R(TTE) analysis workshop

Workshop overview

Target audience

Key topics covered

The motivation for running survival analyses from a model-informed drug development perspective with key speakers from academia and industry (day one is free of charge),
an introduction to general concepts and theory, typical TTE/RTTE analysis followed by data formatting and key aspects of graphical exploration of TTE/RTTE data,
detailed insights to NONMEM code useful for the model development, such as standard and alternative function parameterization, implementation of exposure-response relationships and estimation of covariate effects,
an overview of efficient simulation frameworks, with a focus on NONMEM coding and derived metrics, using graphs for communication,
several hands-on sessions to help you grasp the specificities of TTE/RTTE models in terms of evaluation and diagnostics.

Learning objectives

Workshop faculty

Key speakers

Prof. Lena Friberg

Co-founded Pharmetheus in 2012, advising in client projects and training Pharmetheus colleagues in pharmacometrics
Expertise includes development of pharmacokinetic-pharmacodynamic models of desired and adverse effects in therapeutic areas such as oncology, infectious diseases, and neuroscience
Experience as Professor of Pharmacometrics(2014-2021) and Pharmacokinetics and Pharmacodynamics (2021- ) at Uppsala University, Sweden, where she performs research and teaches in pharmacokinetics, pharmacodynamics, pharmacometrics, and drug development. Previously, she worked as ResearchFellow and Associate Professor at Uppsala University, Sweden, and Postdoctoral Research Fellow at University of Queensland, Australia
M.Sc. in Pharmaceutical Sciences (1997) and Ph.D. in Pharmacokinetics and Drug Therapy (2003) from Uppsala University, Sweden

Prof. France Mentré

Collaborating with Pharmetheus since 2022, in the role as a Scientific Advisor
Expertise includes Biostatistical Modelling and Pharmacometrics for treatment of Infectious Diseases, and development of the software PFIM for optimal design in pharmacometrics
Currently Professor of Biostatistics at University Paris Cité, France, editor in Chief of CPT: Pharmacometrics and System Pharmacology since 2018, and co-founder of the Special Interest Group on Statistics and Pharmacometrics of ASA and ISoP
M.Sc. in Mathematics (1984) from École Normale Supérieure, Ph.D. in Biomathematics (1984) from University Paris 6, M.D. (1993) from University Paris 7, France

Dr. Brendan C. Bender

BB_RTTE_pic-update-1

Currently a Senior Principal Scientist in the Modeling and Simulation (M&S) group at Genentech, Inc.
Recent expertise and contributions include development of pharmacokinetic and pharmacokinetic-pharmacodynamic models for molecules in Genentech’s bispecific drug and antibody drug conjugate (ADC) portfolios.
Employed at Genentech since 2003, with key M&S filing contributions for the ocular drug Lucentis (2006), the ADC drug Kadcyla (2013), and the bispecific drug Lunsumio (2022).
M.Sc. in Pharmaceutical Sciences (2003) from UNC-Chapel Hill and Ph.D. in Pharmaceutical Biosciences (2016) from Uppsala University, Sweden

Workshop tutors

Event details and registration

16cefda6ef73b7faa4df913b326b6999f7619968 (1)